<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343160</url>
  </required_header>
  <id_info>
    <org_study_id>VBR CS 156</org_study_id>
    <nct_id>NCT01343160</nct_id>
  </id_info>
  <brief_title>Removable GORE VIABIL® Biliary Endoprosthesis for Treatment of Benign Biliary Strictures</brief_title>
  <official_title>Multicenter Study of Removable GORE VIABIL® Biliary Endoprosthesis for Treatment of Benign Biliary Strictures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to generate clinical data to support the use of GORE® VIABIL®&#xD;
      Biliary Endoprosthesis in the endoscopic and percutaneous treatment of benign biliary&#xD;
      strictures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safe Stent Removal</measure>
    <time_frame>Upon Removal</time_frame>
    <description>The stent removal is considered safe when the Study Device is removed successfully and without SAEs.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Primary Device Patency</measure>
    <time_frame>12 Months</time_frame>
    <description>Primary device patency is defined as the freedom from device occlusion requiring intervention (during the treatment period).</description>
  </other_outcome>
  <other_outcome>
    <measure>Successful Delivery and Deployment</measure>
    <time_frame>Upon Implant</time_frame>
    <description>This requires successful delivery and deployment of the device at the intended site.</description>
  </other_outcome>
  <other_outcome>
    <measure>Successful Treatment of Benign Stricture Upon Implant</measure>
    <time_frame>Upon implant</time_frame>
    <description>Successful treatment of strictures is defined as stricture resolution upon implant as reported by the PI. For the purpose of this report, we will be referring to this as &quot;stented stricture resolution&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>12 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Viability of Treatment</measure>
    <time_frame>Upon Removal</time_frame>
    <description>Treatment is considered viable when the Study Device is removed and the structure is either resolved or improved without the need for re-stenting at the time of Study Device removal.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Patency Post Study Device Removal</measure>
    <time_frame>15 Months</time_frame>
    <description>Secondary patency post study device removal is defined as the absence of stricture recurrence from time of Study Device removal to study completion or lost to follow up. Secondary Patency is also known as Long Term Stricture Resolution.</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary Patency of Treated Stricture</measure>
    <time_frame>15 Months</time_frame>
    <description>Primary patency of the treated stricture is defined as freedom from stricture intervention due to occlusion following Study Device removal.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Biliary Strictures</condition>
  <arm_group>
    <arm_group_label>GORE VIABIL® Biliary Endoprosthesis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® VIABIL® Biliary Endoprosthesis</intervention_name>
    <description>Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture</description>
    <arm_group_label>GORE VIABIL® Biliary Endoprosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is diagnosed with treatable benign biliary stricture which necessitates the&#xD;
             need for implantation of a biliary endoprosthesis&#xD;
&#xD;
          -  Subject is ≥18 years of age&#xD;
&#xD;
          -  Subject is able to comply with study protocol and follow-up requirements&#xD;
&#xD;
          -  Written informed consent is obtained using the Investigational Review Board&#xD;
             (IRB)/Ethics Committee (EC) approved consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject anatomy ruling out covered self expanding metal stent use (e.g. above hilar&#xD;
             region)&#xD;
&#xD;
          -  Treatment of stricture would require placement of a covered biliary endoprosthesis&#xD;
             within a previously placed bare metal stent&#xD;
&#xD;
          -  The subject has malignant biliary disease&#xD;
&#xD;
          -  Subject has known pregnancy&#xD;
&#xD;
          -  Participated in protocol involving investigational drug or device within 90 days prior&#xD;
             to entry into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karel Caca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Ludwigsburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <results_first_submitted>March 25, 2021</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GORE VIABIL® Biliary Endoprosthesis</title>
          <description>Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency&#xD;
GORE® VIABIL® Biliary Endoprosthesis: Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GORE VIABIL</title>
          <description>GORE® VIABIL® Biliary Endoprosthesis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="07"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safe Stent Removal</title>
        <description>The stent removal is considered safe when the Study Device is removed successfully and without SAEs.</description>
        <time_frame>Upon Removal</time_frame>
        <population>Subjects with stent removal data available</population>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL</title>
            <description>GORE® VIABIL® Biliary Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Safe Stent Removal</title>
          <description>The stent removal is considered safe when the Study Device is removed successfully and without SAEs.</description>
          <population>Subjects with stent removal data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Primary Device Patency</title>
        <description>Primary device patency is defined as the freedom from device occlusion requiring intervention (during the treatment period).</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL</title>
            <description>GORE® VIABIL® Biliary Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Device Patency</title>
          <description>Primary device patency is defined as the freedom from device occlusion requiring intervention (during the treatment period).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" lower_limit="55.9" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Successful Delivery and Deployment</title>
        <description>This requires successful delivery and deployment of the device at the intended site.</description>
        <time_frame>Upon Implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL® Biliary Endoprosthesis</title>
            <description>Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency&#xD;
GORE® VIABIL® Biliary Endoprosthesis: Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Delivery and Deployment</title>
          <description>This requires successful delivery and deployment of the device at the intended site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Successful Treatment of Benign Stricture Upon Implant</title>
        <description>Successful treatment of strictures is defined as stricture resolution upon implant as reported by the PI. For the purpose of this report, we will be referring to this as &quot;stented stricture resolution&quot;.</description>
        <time_frame>Upon implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL</title>
            <description>GORE® VIABIL® Biliary Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Treatment of Benign Stricture Upon Implant</title>
          <description>Successful treatment of strictures is defined as stricture resolution upon implant as reported by the PI. For the purpose of this report, we will be referring to this as &quot;stented stricture resolution&quot;.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Secondary Patency</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL</title>
            <description>GORE® VIABIL® Biliary Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" lower_limit="62.5" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Viability of Treatment</title>
        <description>Treatment is considered viable when the Study Device is removed and the structure is either resolved or improved without the need for re-stenting at the time of Study Device removal.</description>
        <time_frame>Upon Removal</time_frame>
        <population>Subjects with stent removal data available</population>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL</title>
            <description>GORE® VIABIL® Biliary Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Viability of Treatment</title>
          <description>Treatment is considered viable when the Study Device is removed and the structure is either resolved or improved without the need for re-stenting at the time of Study Device removal.</description>
          <population>Subjects with stent removal data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Secondary Patency Post Study Device Removal</title>
        <description>Secondary patency post study device removal is defined as the absence of stricture recurrence from time of Study Device removal to study completion or lost to follow up. Secondary Patency is also known as Long Term Stricture Resolution.</description>
        <time_frame>15 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL</title>
            <description>GORE® VIABIL® Biliary Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency Post Study Device Removal</title>
          <description>Secondary patency post study device removal is defined as the absence of stricture recurrence from time of Study Device removal to study completion or lost to follow up. Secondary Patency is also known as Long Term Stricture Resolution.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" lower_limit="48.0" upper_limit="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Primary Patency of Treated Stricture</title>
        <description>Primary patency of the treated stricture is defined as freedom from stricture intervention due to occlusion following Study Device removal.</description>
        <time_frame>15 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE VIABIL</title>
            <description>GORE® VIABIL® Biliary Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency of Treated Stricture</title>
          <description>Primary patency of the treated stricture is defined as freedom from stricture intervention due to occlusion following Study Device removal.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="45.2" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for patients upto 12 Months of treatment period with the stent and upto 15 Months of post stent removal</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GORE VIABIL</title>
          <description>GORE® VIABIL® Biliary Endoprosthesis</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrence of obstructive jaundice</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Papillary hemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. Sponsor can require changes to the communication as necessary to ensure the proper use of any references to itself, its trademarks, and trade names and to correct inaccuracies in any technical specifications or descriptions of the device, including its component materials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rizwan Afzal</name_or_title>
      <organization>W.L. Gore &amp; Associates</organization>
      <phone>623-234-5408</phone>
      <email>rafzal@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

